Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

626
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
626
Peripheral Artery Disease I: Introduction01:30

Peripheral Artery Disease I: Introduction

646
Peripheral artery disease (PAD) predominantly results from atherosclerosis, which involves the accumulation of fatty deposits, or plaques, within the walls of arteries. This causes them to narrow and harden, significantly reducing blood flow. PAD predominantly affects the legs, particularly the arteries supplying the thighs and calves. In rare cases, it may involve other arteries, including those in the arms.Etiology of PAD:The principal cause of PAD is atherosclerosis, which results from fatty...
646
Peripheral Artery Disease IV: Nursing Management01:26

Peripheral Artery Disease IV: Nursing Management

652
 The nursing management of a patient with peripheral artery disease (PAD) begins with a thorough assessment of the patient’s health history and clinical manifestations.AssessmentHealth History: Evaluate the patient’s history of hypertension, hyperlipidemia, family history of cardiovascular issues, and lifestyle factors such as dietary patterns, smoking, and physical activity.Physical Examination:Assess the affected extremity for decreased or absent peripheral pulses,...
652
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

623
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
623
Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation01:21

Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation

715
Clinical manifestationsPeripheral Arterial Disease (PAD) manifests through a range of symptoms, from the characteristic intermittent claudication to atypical presentations and severe complications in advanced stages. Intermittent claudication, a hallmark symptom of PAD, presents as exercise-induced muscle pain that typically resolves within minutes of rest. This pain is reproducible and stems from inadequate blood flow, leading to the accumulation of lactic acid produced during anaerobic...
715
Gene Therapy00:59

Gene Therapy

28.3K
Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be...
28.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Targeting the hallmarks of aging: mechanisms and therapeutic opportunities.

Frontiers in cardiovascular medicine·2025
Same author

A Role for Periostin Pathological Variants and Their Interaction with HSP70-1a in Promoting Pancreatic Cancer Progression and Chemoresistance.

International journal of molecular sciences·2024
Same author

Expression of Periostin Alternative Splicing Variants in Normal Tissue and Breast Cancer.

Biomolecules·2024
Same author

The Importance of Suppressing Pathological Periostin Splicing Variants with Exon 17 in Both Stroma and Cancer.

Cells·2024
Same author

Experimental Study: The Development of a Novel Treatment for Chemotherapy-Resistant Tongue Cancer with the Inhibition of the Pathological Periostin Splicing Variant 1-2 with Exon 21.

Cells·2024
Same author

Blocking Periostin Prevented Development of Inflammation in Rhabdomyolysis-Induced Acute Kidney Injury Mice Model.

Cells·2022

Related Experiment Video

Updated: Apr 18, 2026

Preclinical Model of Hind Limb Ischemia in Diabetic Rabbits
07:34

Preclinical Model of Hind Limb Ischemia in Diabetic Rabbits

Published on: June 2, 2019

10.5K

Gene therapy in peripheral artery disease.

Fumihiro Sanada1, Yoshiaki Taniyama, Yasuhiro Kanbara

  • 1Osaka University Graduate School of Medicine, Department of Clinical Gene Therapy , Suita, Osaka 565-0871 , Japan.

Expert Opinion on Biological Therapy
|January 31, 2015
PubMed
Summary

Hepatocyte growth factor (HGF) gene therapy shows promise for critical limb ischemia (CLI) patients, unlike previous VEGF and FGF trials. HGF offers unique benefits in managing inflammation and cell aging, improving outcomes for peripheral artery disease.

Keywords:
VEGFangiogenesisfibroblast growth factorgene therapyhepatocyte growth factorperipheral artery disease

More Related Videos

Osmotic Drug Delivery to Ischemic Hindlimbs and Perfusion of Vasculature with Microfil for Micro-Computed Tomography Imaging
10:50

Osmotic Drug Delivery to Ischemic Hindlimbs and Perfusion of Vasculature with Microfil for Micro-Computed Tomography Imaging

Published on: June 29, 2013

12.9K
A Rabbit Model of Durable Transgene Expression in Jugular Vein to Common Carotid Artery Interposition Grafts
13:58

A Rabbit Model of Durable Transgene Expression in Jugular Vein to Common Carotid Artery Interposition Grafts

Published on: September 10, 2018

11.0K

Related Experiment Videos

Last Updated: Apr 18, 2026

Preclinical Model of Hind Limb Ischemia in Diabetic Rabbits
07:34

Preclinical Model of Hind Limb Ischemia in Diabetic Rabbits

Published on: June 2, 2019

10.5K
Osmotic Drug Delivery to Ischemic Hindlimbs and Perfusion of Vasculature with Microfil for Micro-Computed Tomography Imaging
10:50

Osmotic Drug Delivery to Ischemic Hindlimbs and Perfusion of Vasculature with Microfil for Micro-Computed Tomography Imaging

Published on: June 29, 2013

12.9K
A Rabbit Model of Durable Transgene Expression in Jugular Vein to Common Carotid Artery Interposition Grafts
13:58

A Rabbit Model of Durable Transgene Expression in Jugular Vein to Common Carotid Artery Interposition Grafts

Published on: September 10, 2018

11.0K

Area of Science:

  • Vascular Biology
  • Regenerative Medicine
  • Gene Therapy

Background:

  • Critical limb ischemia (CLI) patients face high amputation risk and poor quality of life.
  • Previous angiogenic growth factors (VEGF, FGF) showed limited success in clinical trials for CLI.
  • Hepatocyte growth factor (HGF) gene therapy presents a novel therapeutic strategy for CLI.

Purpose of the Study:

  • To review clinical trial data for gene therapy in peripheral artery disease (PAD).
  • To explore mechanisms underlying the efficacy and limitations of gene therapy trials.
  • To highlight the unique benefits of HGF in CLI treatment.

Main Methods:

  • Analysis of Phase I-III clinical trial data for gene therapy in PAD patients.
  • Examination of molecular mechanisms related to HGF's therapeutic effects.
  • Comparative review of HGF against other angiogenic factors like VEGF and FGF.

Main Results:

  • Recent Phase II and III trials indicate significant benefits of HGF gene therapy for CLI patients.
  • HGF demonstrated efficacy where VEGF and FGF trials failed to show significant improvements.
  • Small patient numbers in HGF trials necessitate further investigation but suggest distinct advantages.

Conclusions:

  • HGF possesses unique anti-inflammatory, anti-fibrotic, and anti-senescence properties.
  • These distinct molecular effects of HGF contribute to its clinical benefits in PAD patients.
  • HGF gene therapy represents a promising advancement for treating CLI.